% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Harrer:45558,
      author       = {Harrer, E. and Bäuerle, M. and Ferstl, B. and Chaplin, I.
                      T. and Petzold, B. and Mateo, L. and Handley, A. and
                      Tzatzaris, M. and Vollmar, J. and Bermann, S. and Rittmaier,
                      M. and Eismann, K. and Miller, S. and Kalden, J. R. and
                      Spriewald, B. and Willbold, D. and Harrer, T.},
      title        = {{T}herapeutic vaccination of {HIV}-1-infected patients on
                      {HAART} with a recombinant {HIV}-1 nef-expressing {MVA}:
                      safety, immunogenicity and influence on viral load during
                      treatment interruption},
      journal      = {Antiviral therapy},
      volume       = {10},
      issn         = {1359-6535},
      address      = {London},
      publisher    = {International Medical Press},
      reportid     = {PreJuSER-45558},
      pages        = {285 - 300},
      year         = {2005},
      note         = {Record converted from VDB: 12.11.2012},
      abstract     = {The safety and immunogenicity of an HIV-1 nef-expressing
                      modified vaccinia virus Ankara (MVA) was investigated in 14
                      HIV-1-positive patients (CD4 > 400/mu l) on highly active
                      antiretroviral therapy (HAART). Patients were vaccinated at
                      weeks 0, 4 and 16, followed by interruption of HAART at week
                      18. MVA-nef was well tolerated except for local reactions,
                      with only mild systemic side effects reported in a few
                      patients. Vaccination with MVA-nef was associated with
                      recognition of new HIV-1 T-cell epitopes (cytotoxic
                      T-lymphocyte epitopes in 9/14 patients, CD4
                      epitope/recombinant Nef protein in 2/14) and an increase in
                      CD4+ and CD8+ T cells. All patients had been vaccinated
                      against smallpox and a strong T-cell and antibody response
                      to MVA was induced in all patients. After interruption of
                      HAART, viral load rebounded in all patients, but after a
                      median time of 36 (4-76) weeks in 9/14 patients, viraemia
                      remained below the pre-HAART viral load and CD4 counts
                      stayed above the pre-HAART levels. While six patients have
                      remained off therapy for a median time of 64 (57-76) weeks,
                      HAART was resumed in 8/14 patients after a median treatment
                      interruption time of 15 (4-38) weeks. This study has
                      demonstrated that MVA-nef is safe and immunogenic in
                      HIV-1-infected subjects and has provided encouraging data on
                      the potential of therapeutic vaccinations.},
      keywords     = {J (WoSType)},
      cin          = {IBI-2},
      ddc          = {610},
      cid          = {I:(DE-Juel1)VDB58},
      pnm          = {Neurowissenschaften},
      pid          = {G:(DE-Juel1)FUEK255},
      shelfmark    = {Infectious Diseases / Pharmacology $\&$ Pharmacy /
                      Virology},
      typ          = {PUB:(DE-HGF)16},
      UT           = {WOS:000231962300011},
      url          = {https://juser.fz-juelich.de/record/45558},
}